Premium
Platinum plus bortezomib for the treatment of pediatric renal medullary carcinoma: Two cases
Author(s) -
Carden Marcus A.,
Smith Stephen,
Meany Holly,
Yin Hong,
Alazraki Adina,
Rapkin Louis B.
Publication year - 2017
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.26402
Subject(s) - medicine , bortezomib , disease , medullary cavity , chemotherapy , renal cell carcinoma , nephropathy , oncology , surgery , multiple myeloma , diabetes mellitus , endocrinology
Renal medullary carcinoma (RMC) was first described over two decades ago as the seventh sickle nephropathy. Survival after diagnosis with metastatic disease still rarely extends beyond 1 year, with recent reports of median overall survival in patients treated with platinum therapy being just 10 months. We describe our experience using platinum‐based chemotherapy plus the proteasome inhibitor bortezomib to treat metastatic RMC in two pediatric patients who had complete responses. One patient passed away 7 years after diagnosis, while another remains disease free nearly 2 years from diagnosis.